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1. Introduction 
Post-inflammatory nephropathy is a progressive renal scarring which may be a consequence 
of one or more episodes of acute pyelonephritis.  
Macroscopically, post-inflammatory nephropathy leads to gradual decrease in kidney size 
and deformity and dilation of pelvicalyceal system. These alternations are due to 
tubulointerstitial fibrosis and glomerular sclerosis followed by renal parenchymal atrophy 
and kidney cirrhosis development (Bernstein, 1994). It was demonstrated that there was 
positive correlation between severity of renal scarring and loss of renal function 
(Eddy et al., 2000; Eddy, 2000). 
Post-inflammatory nephropathy is the leading cause of end-stage renal failure. In Europe, 
children with end-stage renal failure due to post-inflammatory nephropathy constitutes 10-
24% of those on renal replacement therapy (Broyer et al., 1993). 
The development of post-inflammatory nephropathy is influenced by age and gender of 
patient, the number of acute pyelonephritis episodes, the presence of anatomical and/or 
functional urinary system abnormalities, the virulence of invading pathogen, the time of 
appropriate treatment initiation and genetic predisposition. 
The majority of studies demonstrated that the risk of renal scarring decreases with age and 
is highest in children in the first year of life (Hansson et al., 1999; Vernon et al., 1997; Arant, 
1991; Benador et al., 1997; Smellie et al.,1998; Sheu et al., 2009). This may be related to the 
correction of anatomical and/or functional urinary system abnormalities and the decrease in 
susceptibility of renal parenchyma to infection due to defense mechanisms maturation 
(Benador et al., 1997; Rushton et al.,1992). Dissimilar results were obtained by Pecile et al. 
(2009). The authors showed that the lowest risk of renal scarring after first episode of febrile 
urinary tract infection was in children in the first year of life and the highest one - in 
children aged 5 -14 years.  
It was also demonstrated that the male gender is an independent risk factor for renal 
scarring (Silva et al., 2009; Mohanan et al., 2008). 
The risk of post-inflammatory nephropathy development increases with the number of acute 
pyelonephritis episodes. Renal scarring develops in 15% of children after the first episode of 
acute pyelonephritis. After two episodes of acute pyelonephritis renal scarring occurs in 35% 
of children and after three or more episodes – in 60% of children. The study by  Orellana et al. 
(2004) showed that one episode of pyelonephritis caused permanent renal parenchymal injury 
in 55.9% of children whereas recurrent urinary tract infection – in 72.6% of children. 
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Anatomical and functional abnormalities of urinary system particularly predispose to post-
inflammatory nephropathy development, although renal scarring may occur after acute 
pyelonephritis in children without these abnormalities (Gordon et al., 1987; Vanderfaeillie et 
al., 1998). 
Numerous studies emphasized the significance of invading pathogen virulence for post-
inflammatory nephropathy development. P, I and F1C fimbriae of Escherichia coli give rise to 
secretion of interleukins 6 and 8 by uroepithelial cells (Backhed et al., 2001; Hedlund et al., 
1996, 2001). In addition, lipopolysaccharides of Gram-negative bacteria stimulate the release 
of cytotoxic nitric oxide and proinflammatory cytokines (Backhed et al., 2001; De Man et al., 
1989; Traylor & Mayeux, 1997) whereas lipid A stimulates synthesis of nitric oxide (Traylor 
& Mayeux, 1997). Alfa-hemolysins of Escherichia coli give rise to cytolysis (Uhlen et al., 2000) 
and induce apoptosis of tubular cells (Chen et al., 2003, 2004]. 
Immediate initiation of appropriate therapy is of utmost importance in prevention of renal 
scarring development. Antibacterial treatment initiated within 24 hours prevents migration 
of neutrophils to inflammatory foci (Ransley & Risdon, 1981). A delay in initiation of 
therapy increases the risk of renal scarring from 5% to over 15%. 
In numerous studies, the importance of genetic predisposition to renal scarring was  
emphasized. An association between polymorphism of angiotensin-converting enzyme gene 
and renal scarring was demonstrated (Haszon et al., 2002; Hohenfellner et al., 1999; Ohtomo 
et al., 2001; Ozen et al., 1999; Pardo et al., 2003). Similarly,  polymorphism of transforming 
growth factor ǃ gene (Kowalewska-Pietrzak et al., 2008; Hussein et al., 2010) and 
polymorphism of vascular endothelium growth factor gene (Hussein et al., 2010) had impact 
on severity of renal scarring. 
Post-inflammatory nephropathy may be classified into reflux nephropathy due to vesico-
ureteral reflux and obstructive nephropathy due to urinary tract obstruction (Marra et al., 
2004; Orikasa et al., 1995; Smellie et al., 1981).  
2. Pathogenesis of post-inflammatory nephropathy 
Pathogenesis of post-inflammatory nephropathy is complex and not fully understood 
(Fig.1). In the last years, the investigators paid particular attention to the role of molecular 
factors in initiation and progression of post-inflammatory nephropathy. Numerous studies 
concerning molecular mechanisms leading to renal scarring were published (Eddy, 2000; 
Eddy et al., 2000; Guroze et al., 2005; Jahnukainen et al., 2005; Lane et al., 2002, Nath, 1998; 
Solari et al., 2004; Strutz et al., 1995,1996,1999, 2003; Weiss et al., 1994). The process of renal 
scarring may be divided into four phases:  induction, fibrogenic signaling, fibrogenic, and 
destructive phases (Eddy, 2000). Induction phase is also known as cellular activation and 
injury phase. The interstitial space is infiltrated by both neutrophils and monocytes. In acute 
inflammation, the migration of neutrophils is primarily observed whereas in chronic 
inflammation monocytes predominate.  
Neutrophils release numerous cytokines, lysosomal enzymes and free oxygen radicals. In 
addition, neutrophils may activate fibroblasts directly or indirectly via release of elastase 
and thus they participate in fibrogenic process (Bailey, 1973;  Kishimoto & Harano, 1988).  
Monocytes transform into macrophages which also participate in fibrogenic process (Lane et 
al., 2002; Nath, 1998). Solari et al. (2004) demonstrated that in reflux nephropathy, an 
increase in number of mastocytes was observed. Mastocytes produce numerous cytokines 
among others profibrogenic transforming growth factor ǃ (TGF-ǃ) and basic fibroblast 
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Fig. 1. Pathogenesis of post-inflammatory nephropathy. 
growth factor (bFGF). In addition, mastocytes produce enzymes – tryptase and chymase. 
Tryptase stimulates type I collagen production by fibroblasts whereas chymase releases 
TGF-ǃ from inactive complexes and converts angiotensin I to angiotensin II. This suggests 
participation of mastocytes in fibrogenic process.  
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Inflammatory infiltration cells produce other cytokines such as interleukins 1, 6, 8 (IL-1, IL-6, 
IL-8) and tumor necrosis factor ǂ (TNF-ǂ).  
The study by Wolfs et al. (2002) demonstrated that Toll-like receptors-2,-4 (TLR-2, TLR-4) 
were responsible for defense response during acute pyelonephritis. Activated by 
endogenous danger signals TLR-2 expression is also of significance in induction of 
inflammation during progressive renal injury (Leemans et al.,  2009). 
During acute interstitial inflammation activated tubular cells directly participate in 
activation of myofibroblasts and fibroblasts (Abbate et al., 2002; Alpers et al., 1994; Roberts 
et al., 1997) and produce monocyte chemoattractant protein-1 (MCP-1) (Okada et al., 2000), 
endothelin-1 (ET-1) (Bruzzi et al., 1997),  angiotensin II causing vasoconstriction, and 
transferrin (Chen et al., 1998) activating free oxygen radicals (Chertin et al., 2002). 
As a result of acute interstitial inflammation expression of novel antigens on tubular cells 
occurs and these new antigens stimulate an immune response of lymphocyte T which 
enhances inflammation and progression of nephropathy (Szeto et al., 2005).  
In addition, tubular cells and fibroblasts transform into myofibroblasts. This process is 
called epithelial-mesenchymal transformation or transition (EMT). Numerous authors 
confirmed the possibility of EMT (Oldfield et al., 2001; Rastaldi et al., 2002; Strutz et al., 1995; 
Zeisberg et al., 2001).  Myofibroblast, unlike typical interstitial fibroblasts,  are characterized 
by their expression of the myocyte protein ǂ-smooth muscle actin. These cells are 
considerably more profibrotic than interstitial fibroblasts.  
During acute interstitial inflammation activation of complement system via classic and 
alternative pathway is also observed. C3a and C5a component are known to be chemotactic 
for monocytes. There is evidence for participation of complement system in inflammatory 
infiltration formation, tubular atrophy and tubulointerstitial fibrosis (Nangaku et al., 1999).  
In pathogenesis of chronic interstitial inflammation leukocyte adhesion molecules such as 
integrins, selectins and members of the immunoglobulin superfamily (intercellular adhesion 
molecules – ICAMs and vascular cell adhesion molecules – VCAMs) seem to play a crucial 
role but details remain unclear.  ICAMs, VCAMs and osteopontin are chemoattractant for 
monocytes (Okada et al., 2000; Ricardo et al., 1996). 
An early phase of acute interstitial inflammation is reversible provided that nociceptive 
factor is eliminated (Eddy, 2000; Eddy et al., 2000). 
In fibrogenic signaling phase, numerous fibrogenic factors are released, including TGF-ǃ1, 
tissue growth factor (TGF), angiotensin II, ET-1, platelet growth factor (PDGF-BB), bFGF, 
TNF-ǂ, and IL-1. Fibrogenic factors activate their cognate receptors expressed by 
tubulointerstitial cells and subsequent extracellular matrix accumulation along tubular 
basement membranes and within the interstitial space occurs. 
In fibrogenic phase, fibrogenic factors activate a new group of genes that lead to excessive 
accumulation of extracellular matrix proteins and polysaccharides within the interstitial 
space (Beck-Schimmer et al., 1998; Pichler et al., 1996). In this phase, disequilibrium between 
extracellular matrix production and its degradation is observed. 
A main cause of impairment of extracellular matrix remodeling and degradation is a 
decrease in activity of metalloproteinases (MMP) due to induction of tissue inhibitors of 
metalloproteinases (TIMP). Four major TIMP have been identified (TIMP-1, TIMP-2, TIMP-
3, and TIMP-4). In the majority of progressive renal diseases,  marked induction of TIMP-1 is 
observed (Chromek et al., 2003,2004; Eddy et al., 2000; Kim et al., 2001). Within kidney, 
TIMP-1 is produced by tubular  cells, fibroblasts and macrophages. Production of TIMP-1 is 
stimulated by growth factors (TGF-ǃ1, TGF-ǂ, epithelial growth factor (EGF), PDGF, TNF-
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ǂ), interleukins (IL-1, IL-6, IL-10), oncostatin M, endotoxin and thrombin. Recently, the 
induction of plasminogen activator inhibitor-1 (PAI-1) in progressive renal diseases was 
documented. This may suggest its participation in tubulointerstitial fibrosis. PAI-1 is 
produced by tubular cells, fibroblasts and myofibroblasts. Its expression is induced by TGF-
ǃ, EGF, PDGF, TNF-ǂ and bFGF  (as cited in Eddy, 2000). 
In destructive phase, a gradual loss of functioning nephrons occurs as a result of excessive 
accumulation of extracellular matrix. Glomerular sclerosis, peritubular capillaries and 
tubular atrophy lead to progressive renal failure (Orphanides et al., 1997; Seron et al., 1990). 
TGF-ǃ, TNF-ǂ, IL-1ǃ, IL-6 and IL-8 seem to play a major role in renal scarring. 
Transforming growth factor ǃ (TGF-ǃ) 
TGF-ǃ is released primarily by macrophages, neutrophils, lymphocytes and platelets. TGF-ǃ 
is produced as an inactive complex with LAP (latent associated protein) and LTBP (latent TGF-
β binding protein) which are components of extracellular matrix. These proteins have 
potential to store and release of TGF-ǃ. Five isoforms of TGF-ǃ (TGF-ǃ 1-5) have been 
identified. In mammalians, only TGF-ǃ 1-3 are found. Active TGF-ǃ is a homodimeric 25kD 
protein. Within kidneys numerous factors increase TGF-ǃ expression, including angiotensin 
II, endothelin I, interleukin 1ǃ, platelet activating factor (PAF), thromboxane, 
thrombospondin, glucose, insulin, atrial natriuretic peptide (ANP), secreted protein acidic 
and rich in cysteine (SPARC), and hypoxia (Pichler et al., 1996). Increased TGF-ǃ expression 
in kidneys is also caused by TNF-ǂ and connective tissue growth factor (CTGF) (Zhang 
et.al., 2004). In addition, proteoglycans accumulated within the interstitial space may be a 
reservoir of TGF-ǃ. 
TGF-ǃ stimulates production of proinflammatory cytokines (IL-1, IL-6, IL-8 and TNF-ǂ). It is 
known to be chemotactic for monocytes, neutrophils, and fibroblasts. TGF-ǃ stimulates 
production of extracellular matrix proteins such as fibronectin, collagen and proteoglycans. 
In addition, it increases expression of TIMPs. This contributes to depressed activity of MMP 
and stabilization of extracellular matrix (Boettinger & Bitzer, 2002; Boettinger et al., 1997; 
Broder et al., 1994; Cotton et al., 2002; Deng et al., 2006; Fan et al., 1999; Goumneos et al., 
2002; Guo et al., 1997; Jahnukainen et al., 2005; Korzon et al., 2004; Lane et al., 2002; Liapis, 
2003). Poncelet & Schnaper (1998) documented that TGF-ǃ stimulates production of collagen 
I, III and IV by mesangial cells. Experimental studies on transgenic mice showed that 
overexpression of TGF-ǃ resulted in glomerular and interstitial fibrosis (Kelly et al., 1999). In 
experimental model of ureteral obstruction (Shinozaki et al., 1998) and in proteinuric state 
(Jernigan et al., 1996), overexpression of the type II receptor for TGF-ǃ gave rise to increased 
accumulation of collagen within the interstitial space. 
TGF-ǃ induces EMT (Fan et al., 1999; Ng et al., 1998) and inhibits apoptosis of 
myofibroblasts (Zhang & Phan,1999; Fan et al., 1999; Frazier et al., 2000). In addition, TGF-ǃ 
induces apoptosis of endothelial cells. This results in peritubular and glomerular capillaries 
atrophy followed by fibrosis (Choi & Ballermann, 1995; Kang et al., 2002; Ohashi et al., 
2000). TGF-ǃ is also known to induce apoptosis of tubular cells leading to tubular atrophy 
with subsequent fibrosis (Dai et al.,2003; Gobe & Axelsen,1987; Kopp et al., 1996; Lane et al., 
2002; Ortiz et al., 1997; Sanderson et al., 1995).  
Experimental studies demonstrated increased TGF-ǃ mRNA expression during infection 
with Escherichia coli (Khalil et al., 2000). Increased urinary TGF-ǃ excretion was showed in 
children with urinary tract infection (Farmaki et al., 2005). 
An association between TGF-ǃ gene polymorphism and susceptibility to renal scarring was 
observed. Solari et al. (2005) documented that the risk of reflux nephropathy was higher in 
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patients with -509CT and Leu10Pro genotypes. Khalil et al. (2005) showed that 
homozygosity for -509T and Arg25 resulted in more rapid progression of renal failure 
whereas patients with -800GA genotype were less susceptible to renal scarring (Cotton et al., 
2002). 
Numerous studies confirmed a significant participation of TGF-ǃ in pathogenesis of 
obstructive nephropathy (Blom et al., 2001; Chevalier, 2004; Duncan et al., 1999; Kaneto et 
al., 1999; Klahr & Morrissey, 1998, 2002, 2003;  Sato et al., 2003; Schnaper et al., 2003). In this 
type of nephropathy, increased angiotensin II production is observed and angiotensin II 
enhances TGF-ǃ expression. Thus angiotensin II plays a key role in initiating of 
tubulointerstitial fibrosis in obstructive nephropathy. Recently, in patients with 
ureteropelvic junction obstruction, increased urinary TGF-ǃ excretion was observed 
(Almodhen et al., 2009, Sager et al., 2009).  
Tumor necrosis factor ǂ (TNF-ǂ) 
TNF-ǂ also known as cachectin is produced by several cells within kidneys, including 
proximal tubular cells, mesangial cells, interstitial fibroblasts and macrophages. The most 
potent stimulus for TNF-ǂ production is lipopolysaccharides of Gram-negative bacteria. 
TNF-ǂ stimulates production of proinflammatory cytokines (IL-1 and Il-6) by macrophages 
and increases macrophages cytotoxicity. In addition, it is known to be chemotactic for 
fibroblasts and stimulates their proliferation. TNF-ǂ has also antifibrotic effects because it 
enhances collagenase activity and inhibits collagen gene expression. In addition, TNF-ǂ 
diminishes activity of TIMP and increases production of  latent MMP-9 (Nee et al., 2004). 
Profibrogenic effects of TNF-ǂ was confirmed in study by Guo et al. (1999). The authors 
demonstrated less severe renal scarring in mice genetically deficient of receptors specific for 
TNF-ǂ. In addition, TNF-ǂ contributes to renal scarring by releasing IL-1ǃ and TGF-ǃ from 
inflammatory infiltration cells (Jahnukainen et al., 2005). Recently, experimental study 
demonstrated less severe renal scarring in rats with nephritis when monoclonal antibodies 
against TNF-ǂ were administered (Khan et al., 2005). Wolfs et al. (2002) showed that TNF-ǂ 
induced overexpression of TLR-2 and -4. TNF-ǂ contributes to the development of 
obstructive nephropathy. Overexpression of TNF-ǂ is due to increased angiotensin II 
secretion observed in upper urinary tract obstruction. 
Interleukin 1 (IL-1) 
IL-1 is one of the major regulator inflammatory and immune reactions. It may be produced 
by several cells within the kidney, including macrophages, mesangial cells, endothelial cells 
and macrophages. It is also known to be chemotactic for neutrophils and monocytes. Other 
activities of IL-1 include: - stimulation of production of IL-1, IL-6, IL-8 and TNF-ǂ by 
macrophages, - stimulation of production of IL-6 and collagenase by fibroblasts, - 
stimulation of fibroblast proliferation and possibly of extracellular matrix production, - 
activation of endothelial cells, - induction of smooth muscle cells lysis. Fibrosis-promoting 
effects of IL-1 were also demonstrated (Ichino et al.,  2008, Mittal et al.,  2009). It also inhibits 
MMP-9 activity which degrades type IV collagen of extracellular matrix  and diminishes 
activity of IL-1 receptor antagonist (IL-1Ra). 
Vesey et al. (2002, 2002) demonstrated that IL-1ǃ stimulated proliferation of interstital 
fibroblast and enhanced production of type I collagen, fibronectin, TGF-ǃ and nitric oxide.  
Study by Zang et al. (2005) showed that IL-1ǃ induced transformation of tubular cells into 
myofibroblasts. In addition, IL-1ǃ stimulates production of IL-6 and IL-8. This intensifies 
inflammation and promotes interstitial fibrosis (Lonnemann et al., 1995). 
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Kassem et al. (2005) demonstrated increased urinary IL-1ǃ excretion in children with acute 
pyelonephritis. The authors also revealed positive correlation between urinary IL-1ǃ and IL-
8 excretion. The survey by Wetmore et al. (2005) showed an association between IL-1 gene 
polymorphism and occurrence of chronic renal diseases which resulted in impairment of 
renal function. Elevated urinary IL-1ǃ excretion was demonstrated in patients with chronic 
renal failure. The highest urinary IL-1ǃ excretion was observed in pre-dialysis  patients. In 
those patients, considerably higher plasma IL-1Ra level as compared to controls was 
disclosed (Pereira et al., 1994). 
Interleukin 6 (IL-6) 
IL-6 is produced by several cells within kidney, including macrophages, interstitial 
fibroblasts and endothelial cells. The study by Patel et al. (2005) demonstrated that IL-6 
intensified inflammation and impaired renal function. Increased urinary IL-6 excretion in 
children with urinary tract infection and positive correlation between urinary IL-6 excretion 
and severity of proteinuria, hematuria and pyuria were also observed (Benson et al., 1996; 
Gendrel et al., 1998; Jantausch et al., 2000; Nicolle et al, 1993; Otto et al., 1999; Mizuano et al., 
2001). Experimental studies revealed increased expression of renal IL-6 in mice with acute 
pyelonephritis due to ureteral obstruction (Kabore et al., 1999; Rugo et al., 1992) and 
increased serum IL-6 level in the majority of mice with acute pyelonephritis (Rugo et al., 
1992). Khalil et al. (2000) demonstrated increased mortality in mice with acute 
pyelonephritis and IL-6 deficiency. The authors also disclosed more severe histopathological 
changes in kidneys of IL-6 deficient mice. Numerous studies demonstrated that urinary IL-6 
excretion was higher in patients with acute pyelonephritis than in those with asymptomatic 
bacteriuria (Benson et al., 1994; Hedges et al., 1992; Kassem et al., 2005; Ko et al., 1993; Ohta 
et al., 1992; Otto et al., 1999; Roilides et al., 1999). Positive correlation between urinary IL-6 
excretion and the risk of renal scarring was also disclosed (Benson et al., 1996; Jacobson et 
al., 1998; ; Roilides et al., 1999; Tullus et al., 1994). Wang et al. (2001) observed significant 
correlation between urinary IL-6 excretion and renal scars diagnosed by static 
renoscintigraphy in children with vesicoureteral reflux. In those children, there were 
positive correlations between urinary IL-6 excretion and serum ǂ1- microglobulin, ǃ2- 
microglobulin, creatinine levels and urinary albumin excretion. These authors (Wang et al., 
2001) also performed immunohistochemical evaluation of specimens obtained from 
removed scarred kidneys. Overexpression of IL-6 in renal tubules and scars was observed. 
Data on serum IL-6 level in patients with urinary tract infection and post-inflammatory 
nephropathy are scarce and conflicting. Smółko et al. (2004) revealed higher serum IL-6 level 
in children with vesicoureteral reflux of high grade as compared to controls. The study by 
Gokce et al. (2010) showed the similar results. Increased serum IL-6 level was observed 
primarily in patients with febrile urinary tract infection (Benson et al., 1994; Hedges et al., 
1991,1992; Jacobson et al., 1994, 1998).  
IL-6 gene polymorphism influenced susceptibility to urinary tract infections but had no 
effect on renal parenchymal scarring (Cotton et al., 2000). 
Interleukin 8 (IL-8) 
Within kidney IL-8 is produced primarily by macrophages, interstitial fibroblasts, tubular 
and endothelial cells. It has bactericidal and pro-inflammatory activity because it causes 
chemotaxis and degranulation of neutrophils. In patients with acute urinary tract infection 
and post-inflammatory nephropathy, increased serum IL-8 level and increased urinary IL-8 
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excretion were observed (Kassem et al., 2005; Tikhonov et al., 1997;  Haraoka et al., 1996). 
Increased urinary IL-8 excretion is thought to be a marker of vesicoureteral reflux and post-
inflammatory nephropathy (Galanakis et al., 2006; Gokce et al., 2010; Haraoka et al., 1996; 
Smółko et al., 2004). Taha et al. (2003) demonstrated increased urinary IL-8 excretion in 
patients with acute and chronic urinary tract infections. The authors also disclosed higher 
urinary IL-8 excretion in females as compared to males and positive correlation between 
urinary IL-8 excretion and markers of inflammation, including leukocytosis and serum C-
reactive protein level. 
In patients with urinary tract infection, increased urinary IL-8 excretion was observed in 
numerous studies (Jacobson et al., 1994; Kassem et al., 2005; Nicolle et al., 1993; Olszyna et 
al., 2000; Otto et al., 1999; Rao et al., 2001; Sheu et al., 2009; Tullus et al., 1994). Roilides et al. 
(1999) and Ko et al. (1993) revealed increased urinary IL-8 excretion in newborns with 
abnormal static renoscintigraphy result. Increased urinary IL-8 excretion was also revealed 
in  patients with chronic pyelonephritis (Rebenok et al., 1999; Tikhonov et al., 1997). 
Experimental studies in mice and rabbits with urinary tract infection and without or 
mutated IL-8 receptor disclosed more severe course of infection, massive renal scarring and 
considerable impairment of renal function (Frendeus et al., 2001; Hang et al., 2000). The 
authors suggested that overproduction of IL-8 promoted clearance of bacteria from kidneys 
and thus diminished the risk of renal scarring. There is an opinion that overproduction of 
IL-8 in response to urinary tract infection results in univocal and distinct symptoms leading 
to prompt diagnosis and early initiation of appropriate treatment and thus diminishes the 
risk of renal scarring (Jahnukainen et al., 2005). 
2.1 Reflux nephropathy 
Reflux nephropathy (RN) refers to renal scarring due to vesicoureteral reflux. Chronic renal 
failure as a result of RN is observed in 5%-40% of children aged below 16 years and in 5%-
20% of adults (Kenda et al., 1997; Noe, 1992; Wan &Greenfield, 1996). RN is also a frequent 
cause of end-stage renal failure.  
Vesicoureteral reflux is a back-flow of urine from the bladder into the ureter and 
pelvicalyceal system. The back-flow of urine from pelvicalyceal system into collecting ducts 
is called intrarenal reflux. When urine is infected, intrarenal reflux results in renal infection. 
The prevalence of intrarenal reflux is particularly high in children aged below 5 years. In 
1960, Hodson and Edwards (as cited in Sieniawska & Wyszyńska, 2003) first demonstrated 
that there was association between vesicoureteral reflux and chronic pyelonephritis. 
Antenatal renal damage due to vesicoureteral reflux may also develop (Arant, 1991; Bailey, 
1973; Lerner, 1994; Smellie, 1975; Peters & Rushton, 2010). 
Classification of grades of vesicoureteral reflux according to International Reflux study 
Committee, (1981) is showed on Fig. 2. 
Vesicoureteral reflux may be primary or secondary. Primary vesicoureteral reflux is due to 
congenital abnormal lateralization of ureteral orifice. Secondary vesicoureteral reflux is a 
result of anatomical and/or functional abnormalities of lower urinary tract. 
Primary vesicoureteral reflux is the most common congenital abnormality of urinary system 
and is diagnosed in 20% - 60% of children with urinary tract infection (Ataei et al., 2004; 
Zajaczkowska et al., 2001; Alvarez et al., 2009). In the noninfected general population, the 
prevalence of vesicoureteral reflux is 1% -2% and in siblings of children with vesicoureteral 
reflux and urinary tract infection – 5% -50% (Noe, 1992). 
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Fig. 2. The International Reflux Study classifies reflux grades as follows: I) reflux into ureter 
only; II) reflux into ureter, pelvis, and calyces, no dilation, normal calyceal fornices; III) mild 
or moderate dilation and/or tortuosity of the ureter and mild or moderate dilation of renal 
pelvis but no or little blunting of the fornices; IV) moderate dilation and/or tortuosity of the 
ureter and moderate dilation of the renal pelvis and calyces V) gross dilation and tortuosity 
of the ureter and gross dilation of the renal pelvis and calyces. Papillary impressions are no 
longer visible in the majority of calyces. There is complete obliteration of the sharp angle of 
the fornices, but maintenance of papillary impressions in major calyces. 
Relation between urinary tract infection, vesicoureteral reflux and renal scarring has been 
known since a long time (Bailey, 1973; ; Kincaid-Smith,1975; Smellie et al., 1975; Van den 
Abbeele et al., 1987). In the early 1970s, Bailey (1973) coined the term “reflux nephropathy” 
to describe renal scarring in patients with vesicoureteral reflux. The study by Sheikh et al. 
(2010) confirmed higher risk of renal scarring in patients with vesicoureteral reflux. Orellana 
et al. (2004) demonstrated that prevalence of renal scarring is higher in children with 
vesicoureteral reflux than in those without that anomaly (72% versus 52%). In addition, it 
was revealed significant association between vesicoureteral reflux diagnosed after first 
episode of urinary tract infection and chronic renal failure (Marra et al., 2004). 
Previously, vesicoureteral reflux was thought to be an independent risk factor for renal 
scarring. Nowadays, this hypothesis is questioned. However, an association between 
urinary tract infection in children with vesicoureteral reflux and renal scarring remains 
unquestionable (Faust et al., 2009; Jahnukainen et al., 2005; Muinuddin et al., 2008). This was 
confirmed by recent studies that demonstrated an increase in the risk of renal scarring after 
acute pyelonephritis in patients with vesicoureteral reflux (Kanellopoulos et al., 2006; Lee et 
al., 2006; Polito et al., 2006; Oh et al., 2008). Studies by Svensson et al. (2005) and Mohanan et 
al. (2008) disclosed that renal scarring was detected less frequently in infants with 
vesicoureteral reflux and without urinary tract infection than in those with vesicoureteral 
reflux and urinary tract infection. In study by Ylinen et al. (2003) renal scarring was found 
more frequently in infants in whom vesicoureteral reflux was diagnosed after the first 
episode of urinary tract infection than in those in whom vesicoureteral reflux was detected 
antenatally. The risk of acute pyelonephritis and thus renal scarring increases along with 
grade of vesicoureteral reflux (Arant, 1991; Oh et al.,  2008, Shaikh et al., 2010, Silva et al., 
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2010) because vesicoureteral reflux of high grade occurs throughout micturition in contrast 
to vesicoureteral reflux of low grade which occurs only at the  peak of micturition 
(Jacobsson et al., 1992). 
In the last years, an association between ACE gene polymorphism and development/ 
progression of RN was demonstrated. The D allele of ACE gene polymorphism was 
associated with higher converting enzyme activity and thus higher concentration of 
angiotensin II in plasma and tissues. This resulted in more rapid development and 
progression of RN (Haszon et al., 2002; Hohenfellner et al., 1999; Ohtomo et al., 2001; Ozen 
et al., 1999). Some studies questioned the significance of ACE gene polymorphism as an 
independent risk factor for the development and progression of RN (Dudley et al., 2002; 
Pardo et al., 2003). An association between TGF-ǃ1 gene polymorphism and the risk of renal 
scarring in patients with vesicoureteral reflux was also disclosed Kowalewska-Pietrzak et al. 
(2008), whereas Hussein et al. (2010) demonstrated an association between vascular 
endothelium growth factor (VEGF) gene polymorphism and the risk of the development of 
RN. 
2.2 Obstructive nephropathy 
Obstructive nephropathy (ON) refers to renal scarring due to mechanical obstruction to 
urine flow (Liapis, 2002). 
Obstruction to urine flow may be congenital or acquired. It can occur at any level of urinary 
tract, including renal tubules, renal pelvis, ureters, bladder and urethra. Obstruction to urine 
flow most commonly occurs at ureteropelvic junction (Koff, 1990; Norbeck et al., 1993). The 
severity of obstructive nephropathy depends on severity of obstruction, its location and 
duration, age of occurrence and concomitant infection. 
Complete or severe obstruction to urine flow leads to obstructive nephropathy more rapidly 
than incomplete one. In addition, the higher the obstruction is located the more severe 
obstructive nephropathy develops. Age of patient is of great significance. Fetal and neonatal 
kidneys are at greatest risk for damage. Antenatal urinary tract obstruction disturbs kidney 
development and results in polycystic dysplasia or hypodysplasia (Chevalier, 2004).  
Re-expression of Pax-2 (Li et al., 2010) gene and decreased expression of Bcl-1 gene (Zhang 
et al. 2001) enhance susceptibility to the development of obstructive nephropathy.  
In the development and progression of obstructive nephropathy, primarily cytokines and 
vasoactive substances are implicated (Chevalier, 2004; Chevalier et al., 2009; Chiou et al., 
2004; Grande et al.,2010; Klahr, 2001; Klahr & Marrissey, 1998, 2002, 2003; Rice et al., 2004). 
Nowadays, TGF-ǃ1 and TNF-ǂ are thought to play a crucial role in renal damage. 
Obstruction to urine flow and alternations in intra- renal hemodynamics result in increased 
secretion of angiotensin II which in turn enhances TGF-ǃ1 and TNF-ǂ expression (Grande et 
al., 2010; Leonova et al., 2007; Manucha, 2007; Padillo et al.,  2007; Pimentel et al., 1995; Sager 
et al., 2009; Wang et al.,2010). Due to urine stasis urinary tract infection may develop. 
Infection is an additional factor which causes renal damage. 
Bilateral complete or severe urinary tract obstruction are the most dangerous anomalies. In 
this clinical settings, even early surgery does not always protect kidneys from permanent 
damage leading to end stage renal failure during childhood (Chevalier et al., 2000). Patients 
after surgical correction of urinary tract obstructions requires careful monitoring in order to 
early detect of obstructive nephropathy symptoms and initiation of nephroprotective 
therapy. 
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3. History and clinical manifestations of post-inflammatory nephropathy 
The clinician needs to obtain a detailed history about the type and duration of symptoms. 
Most often there is a history of recurrent urinary tract infections which cease or occur less 
frequently after surgical correction of anatomical anomaly, appropriate therapy of 
functional disturbances of lower urinary tract and/or antibacterial prophylaxis. Severe and 
developed early in life post-inflammatory nephropathy leads to dwarfism and body weight 
deficit (Polito et al., 1999; Seidel et al., 1993). The patient may  complain of  loin or 
abdominal pain which may be a result of  urinary tract infection, dilation of urinary tract 
due to obstruction or urolithiasis secondary to urine stasis. The patient should be asked 
questions about difficulty initiating urination, decreases in the force of urine stream, 
posturination dribbling, and incomplete emptying. In addition, the patient should be 
questioned about nocturia as chronic renal failure is characterized by the lack of ability to 
concentrate urine during the night. Post-inflammatory nephropathy may also be 
asymptomatic. 
20% of children with post-inflammatory nephropathy develop end-stage renal failure before 
18th year of age and approximately  50% of them - in the fourth decade of life . 
Post-inflammatory nephropathy may lead to arterial hypertension due to ischemia of  renal 
scars and resultant increase in renin production (Wyszynska & Litwin, 2000). Arterial 
hypertension develops most commonly in patients with diffuse bilateral renal scarring 
(Hamed et al., 1992; Kohler et al., 1997, 2003). According to Rushton (1997) it may occur at 
any age but its beginning is most commonly observed in the third decade of life. Arant  
(1991) diagnosed arterial hypertension in 20% of children with post-inflammatory 
nephropathy and the majority of them was over 5 years of age. In Polish children aged 7 -10 
years with post-inflammatory nephropathy, the prevalence of arterial hypertension was 
approximately 50% (Wyszynska & Litwin, 2000). In children with obstructive nephropathy, 
arterial hypertension seems to be sodium-dependent and occurs more commonly when 
urinary tract obstruction is bilateral.  
A late consequence of post-inflammatory nephropathy may be urolithiasis which was 
observed in 18% patients with renal scarring (Kohler et al., 2003; Vachvanichsanong, 2007). 
In pregnants with reflux nephropathy, recurrent urinary tract infections, arterial 
hypertension, gestosis and/or renal failure may occur (Vachvanichsanong, 2007) therefore 
they are at risk for spontaneous abortion and premature delivery. Increased mortality of 
newborns from these mothers was observed. 
4. Diagnosis of post-inflammatory nephropathy 
Diagnostics of post-inflammatory nephropathy include laboratory and imaging studies. 
Initially, urinalysis may be normal or may show sparse proteinuria and/or microhematuria. 
Proteinuria may gradually increase with time. Slightly decreased ability to concentrate and 
acidify urine may also be observed (Polito et al., 1999; Seidel et al., 1993).  
An acetyl-beta-D-glucose aminidase and ǃ2-microglobulin are a widely used markers of 
tubulointerstitial fibrosis. Recently, early and more specific markers of tubulointerstitial 
fibrosis have been introduced such as neutrophil gelatinase-associated lipocalin (NGAL) 
(Ichnio et al., 2010; Wasilewska et al., 2011), kidney injury molecule-1 (KIM-1) (Wasilewska 
et al., 2011], type IV collagen and gluthatione S-transferases alpha and pi (GST-ǂ and GST-π) 
(Cawood et al., 2010, Branten et al., 2000). GST-ǂ is a marker of proximal tubular injury 
www.intechopen.com
 
Urinary Tract Infections 
 
320 
whereas GST-π –distal tubular injury. Chromek et al. (2003, 2004) recommended ratios of 
MMP-1, MMP-2 and MMP-9 to their tissue inhibitors TIMP-1 and TIMP-2 as markers of 
tubulointerstitial fibrosis. 
Valuable diagnostic clues are provided  by radiologic evaluation, including  
ultrasonography, static renoscintigraphy (99mTc DMSA) and dynamic renoscintigraphy 
(99mTcDTPA, 99mTcEC, 99mTcMAG-3). Urography and voiding cystourethrography 
(VCUG) are also helpful. 
Kersnik et al. (2002) evaluated ultrasonography efficacy in detection of renal scarring. They 
demonstrated that sensitivity of ultrasonography in detection of benign, moderate and 
severe renal scarring was 34.1%, 79.2% and 100%, respectively. The study by Moorthy et al. 
(2004) revealed that in detection of renal scarring, ultrasonography  was characterized by 
higher specificity (91.8%) and lower sensitivity (47.2%) as compared to static 
renoscintigraphy. At present, ultrasonography still remains an important tool in evaluation 
of renal scarring. 
The advent of static renoscitigraphy using dimercaptosuccinic acid labeled by 99m 
technetium (99mTcDMSA) was a turning-point in diagnostic evaluation of post-
inflammatory nephropathy.  99mTcDMSA is thought to be the gold standard for detection 
and monitoring of renal scarring. 99mTcDMSA undoubtedly contributes to expansion of our 
knowledge concerning pathogenesis of post-inflammatory nephropathy (Gordon, 1987; 
Orleana et al., 2004; Rushton, 1997; Shapiro et al., 1988; Smellie, 1985; Stokland et al., 1996). 
On the basis of 99mTcDMSA, the classification of severity of renal scarring was made (Fig. 
3.) (Goldraich et al., 1983).  
 
     
 0                            1°                              2°                              3°                              4° 
Fig. 3. Classification of renal scarring according to findings at 99mTcDMSA renal scan: 0 – 
normal, 1° - no more than 2 scarred areas, 2° -  more than 2 scars with some areas of normal 
parenchyma, 3° - generalized damage to the whole kidney, 4° - cirrhotic kidney with little or 
no uptake of DMSA. 
Dynamic renoscintigraphy also has potential to detect renal scarring reliably (Gad et al., 
2004; Narayana et al., 2004). In addition, it evaluates renal function as well as status of 
pelvicalyceal systems and ureters. In dynamic renoscintigraphy, diethylene 
triaminepentaacetic acid (DTPA), ethylenodicysteine (EC), and mercaptoacetyltriglycerin 
(MAG-3) labeled by 99m technetium are used.  
Nowadays, urography is performed less commonly because there are more effective 
methods of urinary system visualization. In addition, urography is viewed as more harmful 
than beneficial for patients. Urography enables to evaluate renal size and margins. It also 
visualizes pelvicalyceal systems and ureters and thus has potential to detect anatomical 
obstruction location. 
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VCUG is performed in order to detect vesicoureteral reflux and anatomical anomalies of the 
bladder and urethra. In the presence of vesicoureteral reflux, VCUG  may demonstrate 
dilation and deformity of renal calyces and occasionally intrarenal refluxes. VCUG may give 
only a suspicion of post-inflammatory nephropathy. VCUG  visualizes the bladder and 
urethra and thus has potential to detect anatomical obstruction to urine flow. Instead of 
VCUG videocystometry is more and more commonly performed because it is able to detect 
both vesicoureteral reflux and anatomical/functional abnormalities of lower urinary tract. 
5. Management of post-inflammatory nephropathy 
Management of post-inflammatory nephropathy include therapy and prophylaxis of 
urinary tract infection, correction of anatomical and functional abnormalities of urinary tract 
and nephroprotection based primarily on inhibition of production or activity of  TGF-ǃ. 
Nowadays, a proven nephroprotective activity is displayed by angiotensin-converting 
enzyme inhibitors, angiotensin II receptor blockers (Khalil et al., 2000, Wang et al., 2005), 
aldosterone antagonists (eplerenone), renin inhibitors (aliskiren) and anti-oxidants (ǂ-
tocopherol) (Chan et al., 2001; Cojocel et al., 2005; Saborio et al., 2000). 
Novel drugs which inhibit tubulointerstitial fibrosis include low-molecular leucine-rich 
proteoglycans, decorin, and biglycan. They have potential to permanent bond with TGF-ǃ 
and thus they inhibit its activity (Solari et al., 2005). Inhibition of tubulointerstitial fibrosis 
was also observed after blockade of type II TGF-ǃ receptor (Jernigan et al., 1996; Kasuga et 
al., 2001; Kushibiki et al., 2005) and as a result of therapy with antibodies against TGF-ǃ 
(Gagliardini & Benigni, 2006). Inhibition of activity of tissue transglutaminases which 
participate in activation of TGF-ǃ  may be a therapeutic option in patients with post-
inflammatory nephropathy in future (Shweke et al., 2008). Other factors which are likely to 
inhibit tubulointerstitial fibrosis are hepatocyte growth factor (HGF) (Mizuno et al., 2001) 
and bone morphogenic protein 7 (BMP-7) (Kopp, 2002). The latest studies demonstrated 
nephroprotective activity of Lefty-A which inhibits and even reverses transformation of 
tubular cells into myofibroblasts (Li et al., 2010, Yao et al., 2011). 
6. Serum concentrations of selected cytokines in children with reflux and 
obstructive nephropathy – original studies  
The purposes of the study were - to assess serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, IL-6 and IL-8  levels 
in children with  post-inflammatory nephropathy (reflux and obstructive nephropathy), - to 
compare serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, IL-6 and IL-8  levels between children with unilateral 
and bilateral vesicoureteral reflux, and between those with vesicoureteral reflux of high and 
low grade, - to compare serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, IL-6 and IL-8 levels between children 
with and without hypertension, and between those with and without proteinuria.  
Patients and methods: The study comprised 70 children (24 boys and 46 girls) aged 1-17 
years with renal scarring diagnosed scintigraphically. All children had a history of recurrent 
urinary tract infections including at least one episode of acute pyelonephritis. Vesicoureteral 
reflux and unilateral ureteropelvic/vesicoureteric junction obstruction were detected in 
85.7% (60/70) and 14.3% (10/70) of children, respectively. Arterial hypertension was 
diagnosed in 17.2% (12/70) of patients. Proteinuria was observed in 25.7% (18/70) of 
children. Renal insufficiency developed in 5,7% (4/70) of patients. Serum TGF-ǃ1, TNF-ǂ, IL-
1 ǃ, IL-6 and IL-8  concentrations were measured by ELISA. 
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Results: In children with reflux/obstructive nephropathy, the mean serum TGF-1 and IL-1ǃ 
concentrations were significantly lower than in controls. Similarly, serum IL-8 
concentrations were lower in both studied groups than in controls but the differences were 
not statistically significant. There were no statistically significant differences in the mean 
serum TNF- and IL-6 concentrations between children with reflux/obstructive 
nephropathy and controls.  
There were no statistically significant differences in the mean serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, 
IL-6 and IL-8 levels between children with unilateral vesicoureteral reflux and those with 
bilateral vesicoureteral reflux. There were also no statistically significant differences in the 
mean serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, IL-6 and IL-8 levels between children with 
vesicoureteral reflux of high grade and those with vesicoureteral reflux of low grade. 
Statistically significant differences in the mean serum TGF-ǃ1, TNF-ǂ, IL-1 ǃ, IL-6 and IL-8  
levels between children with arterial hypertension and the remaining patients were not 
observed. 
In children with proteinuria, the mean serum TGF-ǃ1 level was significantly lower than in 
the remaining patients. There were no statistically significant differences in the mean serum 
TNF-ǂ, IL-1 ǃ, IL-6 and IL-8  levels between children with proteinuria and the remaining 
patients.   
7. Conclusions 
1. The low serum TGF-1 and IL-1ǃ concentrations in patients with reflux and obstructive 
nephropathy seems to be a result of increased influx of this cytokines into renal 
parenchyma and/or increased urinary TGF-1 and IL-1ǃ excretion due to tubular 
damage associated with nephropathy. 
2. The lower serum concentration of TGF-1  in patients with proteinuria secondary to 
post-inflammatory nephropathy may confirm participation of this factor in progression 
of nephropathy 
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